Pfizer Inc. (PFE)
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offer
Metsera said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86.20 per share, for a total of around $10 billion.
Pfizer's revenue falls as COVID sales and vaccine recommendations continue to fade
The full-year outlook was lifted, but the stock lost ground.
Pfizer's Q3: Stagnation Continues
Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect poor growth prospects, making sector comparisons misleading.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.06 per share a year ago.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025)
Shares of Pfizer ( NYSE: PFE ) lost 9.90% over the past month after gaining 10.02% the month prior.
Pfizer raises 2025 profit forecast for second time in a row
Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner.
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech
Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.
Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera
Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.
Is It Time to Dump Your Shares of Pfizer?
After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon.
Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera
The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.
Pfizer sues Metsera, Novo Nordisk over breach of merger deal
Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.
